Phase Ib Study of Nintedanib Monotherapy for Advanced Pancreatic Cancer
Summary
The purpose of this phase I study is to evaluate the safety and tolerability of nintedanib when combined with standard chemotherapy (Gemcitabine + nab-Paclitaxel) for metastatic pancreatic cancer. It will utilize advanced imaging correlates including dynamic contrast enhanced Magnetic Resonance Imaging (DCE-MRI) which correlates with tumor grade and microvessel density.
General Information
NCT#: NCT02902484
Study ID: STU 022016-083
Trial Phase: Phase I
Trial Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc., University of Texas Southwestern Medical Center
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Nintedanib